Sugi Predict

Sugi Predict / Compounds / SCHEMBL1469604

SCHEMBL1469604

SCHEMBL1469604

O=C(O)NC1CCCCNC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 6/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ SLC6A1 P30531 2/20 0.44
▸ SLC6A11 P48066 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ SLC6A13 Q9NSD5 1/20 0.44
▸ MAPK1 P28482 1/20 0.43
▸ OPRK1 P41145 1/20 0.43
▸ CHEK1 O14757 1/20 0.42
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ PBK Q96KB5 2/20 0.39
▸ CPN1 P15169 1/20 0.39
▸ CPB2 Q96IY4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5555738 1.00 EPHX1 (0.46) EPHX1SMN1; SMN2SLC6A1SLC6A11TSHR
SCHEMBL20824836 1.00 EPHX1 (0.46) EPHX1SMN1; SMN2SLC6A1SLC6A11TSHR
SCHEMBL475548 0.94 SLC6A1 (0.50) EPHX1SMN1; SMN2SLC6A1SLC6A11TSHR
SCHEMBL148965 0.94 SLC6A1 (0.50) EPHX1SMN1; SMN2SLC6A1SLC6A11TSHR
SCHEMBL1968950 0.94 SLC6A1 (0.50) EPHX1SMN1; SMN2SLC6A1SLC6A11TSHR
Hydrochloric Acid SCHEMBL17560394 0.92 SLC6A1 (0.48) EPHX1SMN1; SMN2SLC6A1SLC6A11TSHR
SCHEMBL184265 0.85 — —
SCHEMBL1749149 0.85 — —
SCHEMBL512691 0.85 — —
Hydrochloric Acid SCHEMBL23778361 0.83 EPHX1 (0.50) EPHX1SMN1; SMN2SLC6A1SLC6A11TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665733-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 Bristol-Myers Squibb Company (US) 2025-12-24 — — EP disclosed
EP-4419532-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-08-28 — — EP disclosed
WO-2024173323-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-22 — — WO disclosed
CN-118302418-A Aromatic heterocyclic compound and application thereof 中国科学院上海药物研究所 2024-07-05 — — CN disclosed
CN-113840820-B Phthalazinone compounds and uses thereof ST制药株式会社 2024-05-03 — — CN disclosed
WO-2024054512-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-03-14 — — WO disclosed
CN-116102533-A Aromatic heterocyclic compound and application thereof 中国科学院上海药物研究所 2023-05-12 — — CN disclosed
WO-2023066825-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-27 — — WO disclosed
CN-115697987-A Estrogen receptor modulator compounds and uses thereof 江苏先声药业有限公司 2023-02-03 — — CN disclosed
CN-110194770-B Peptidyl arginine deiminase inhibitors and uses thereof 药捷安康(南京)科技股份有限公司 2022-08-09 — — CN disclosed
US-8981085-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-03-17 — — US disclosed
US-20140243520-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-08-28 — — US disclosed
US-8758830-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-06-24 — — US disclosed
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-04-10 — — US disclosed
US-8545897-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-10-01 — — US disclosed
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2013-02-21 — — US disclosed
US-8178131-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-05-15 — — US disclosed
EP-2307409-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-04-13 — — EP disclosed
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-24 — — US disclosed
WO-2009140320-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243520-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A EPHX1 3053/4885SMN1; SMN2 1362/4885SLC6A1 4551/4885
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A EPHX1 3053/4885SMN1; SMN2 1362/4885SLC6A1 4551/4885
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B EPHX1 3109/4885SMN1; SMN2 1386/4885SLC6A1 4598/4885
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A EPHX1 3053/4885SMN1; SMN2 1362/4885SLC6A1 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.